

THERAPIES AND DIAGNOSTICS FOR UTERINE CANCER



HLC142A
September 2013

Usha Nagavarapu
Project Analyst

ISBN: 1-56965-561-8

bcc | Research
Market Forecasting

BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481
866-285-7215, 781-489-7301
www.bccresearch.com
Custom Reports:
carol.laverty@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVES	2
REASONS FOR DOING THIS STUDY	2
INTENDED AUDIENCE	2
SCOPE OF THE STUDY	3
METHODOLOGY	3
INFORMATION SOURCES	3
ABOUT THE AUTHOR	4
RELATED BCC REPORTS	4
BCC ONLINE SERVICES	4
DISCLAIMER	4
CHAPTER 2 SUMMARY	7
<i>SUMMARY TABLE UTERINE/ENDOMETRIAL CANCER: TREATMENT AND DIAGNOSTICS, GLOBAL MARKET AND FORECAST, THROUGH 2018 (\$ MILLIONS)</i>	8
<i>SUMMARY FIGURE UTERINE/ENDOMETRIAL CANCER: TREATMENT AND DIAGNOSTICS, GLOBAL MARKET AND FORECAST, 2012-2018 (\$ MILLIONS)</i>	9
CHAPTER 3 OVERVIEW	11
GYNECOLOGIC CANCERS	11
CANCER	11
<i>TABLE 1 LIFESTYLE CHANGES THAT HELP REDUCE THE PREVALENCE OF CANCER</i>	12
ENDOMETRIAL/UTERINE CANCER	13
<i>TABLE 2 KEY CLINICAL FEATURES OF UTERINE CANCER</i>	13
<i>TABLE 3 HISTOLOGY OF ADENOCARCINOMA</i>	15
CAUSES/RISK FACTORS	15
Hormone Factors	16
<i>TABLE 4 RISK FACTORS</i>	16
Estrogen	17
Estrogen Therapy	17
Oral Contraceptives	17
Total Number of Menstrual Cycles	17
Pregnancy	17
Obesity	18
Treatment with Tamoxifen	18
Ovarian Tumors	18
Polycystic Ovarian Syndrome	18
Use of an Intrauterine Device	19
Age	19
Diet and Exercise	19
Diabetes	19
Genetics	19
<i>TABLE 5 GENES: CAUSE OF HEREDITARY NONPOLYPOSIS COLON CANCER (HNPCC)</i>	20
Breast Cancer	20
Prior Pelvic Radiation Therapy	20
Endometrial Hyperplasia	20

TOPIC	PAGE NO.
CLASSIFICATION	20
Carcinoma	20
<i>TABLE 6 ENDOMETRIAL CARCINOMAS CLASSIFIED INTO TWO PATHOGENETIC GROUPS</i>	21
Sarcoma	21
<i>TABLE 7 CARCINOMA OF THE ENDOMETRIUM</i>	22
ENDOMETRIAL CANCER SYMPTOMS	22
<i>TABLE 8 SIGNS AND SYMPTOMS</i>	23
DIAGNOSIS	23
Clinical Evaluation	23
<i>TABLE 9 UTERINE CANCER: DIAGNOSIS</i>	24
Tests	24
<i>TABLE 10 DIAGNOSTIC TESTS</i>	24
<i>TABLE 11 STAGES OF ENDOMETRIAL CANCER</i>	25
Pathology	25
TREATMENT	26
<i>TABLE 12 TREATMENT DEPENDS UPON THE STAGE</i>	26
Uterine Cancer Treatment is Based on Several Important Factors	27
PROGNOSIS	28
Survival Rates	28
<i>TABLE 13 FIVE-YEAR SURVIVAL RATES (%)</i>	29
<i>TABLE 14 UTERINE CARCINOSARCOMA: FIVE-YEAR SURVIVAL RATES BY STAGE (%)</i>	29
EPIDEMIOLOGY	30
COMPLICATIONS	30
PREVENTION	30
CHAPTER 4 UTERINE CANCER: BIOLOGY	32
UTERUS AND ENDOMETRIUM	32
UTERINE CANCER	32
<i>TABLE 15 TYPES OF UTERINE CANCERS</i>	33
CLINICAL PRESENTATION	33
ESTROGEN'S ROLE	34
TYPES OF ENDOMETRIAL CANCER	34
Carcinoma	34
Type I Endometrial Carcinoma	34
Type II Endometrial Carcinoma	35
Endometrioid Cancer: Grade	35
<i>TABLE 16 GRADING</i>	35
Uterine Sarcomas	36
TUMOR MARKERS	36
Types of Gynecologic Tumor Markers	37
<i>TABLE 17 IMPORTANT GYNECOLOGIC TUMOR MARKERS</i>	37
<i>TABLE 18 POTENTIAL GYNECOLOGIC TUMOR MARKERS</i>	37
Clinical Usefulness of Tumor Markers	38
Expression of L1CAM Protein Predicts Recurrence of Endometrial Cancer	38
GENOMIC CLASSIFICATION OF ENDOMETRIAL CANCERS	39
Treatment Planning Based on Genomic Information: Advantages	39

TOPIC	PAGE NO.
Study Details	40
Summary/Key Facts from the Study	41
<i>TABLE 19 UTERINE CANCER GENOMIC SUBTYPES: KEY CHARACTERISTICS</i>	42
CONCLUSIONS	42
CHAPTER 5 UTERINE CANCER DIAGNOSIS AND SCREENING	45
SCREENING FOR ENDOMETRIAL CANCER	45
CAN ENDOMETRIAL CANCER BE FOUND EARLY?	45
Early Detection Tests	46
STAGING	46
<i>TABLE 20 STAGING OF UTERINE CANCER</i>	46
SCREENING PROCEDURES	46
Low Endometrial Cancer Risk	46
High Endometrial Cancer Risk	47
Current Screening Methods	47
Endometrial Cancer Diagnosis	47
Clinical Evaluation	48
DIAGNOSTIC TESTS FOR ENDOMETRIAL CANCER	48
<i>TABLE 21 UTERINE CANCER SCREENING TESTS OR PROCEDURES</i>	48
Dilatation and Curettage (D&C)	48
Pap Test	49
Transvaginal Ultrasound	49
Hydroultrasound	49
Endometrial Biopsy	50
Hysteroscopy	50
Other Lab Tests	50
Tumor Markers	50
Other Tests	51
Routine Blood Tests	51
New Test: GynEC-Dx	51
<i>TABLE 22 GYNECDX KEY FEATURES</i>	52
CHAPTER 6 UTERINE CANCER TREATMENT STRATEGIES	54
ENDOMETRIAL CANCER RESEARCH	54
HISTOPATHOLOGICAL CHARACTERISTICS	55
MOLECULAR PATHOLOGY OF ENDOMETRIAL CANCER	55
TUMOR MARKERS	55
TREATMENT STRATEGIES	56
SURGERY	56
Surgical Treatment in Stage I Endometrial Cancer	57
Surgical Treatment in Stage II Endometrial Cancer	57
Surgical Treatment in Stage III-IV Endometrial Cancer	57
Hysterectomy	57
<i>TABLE 23 CONDITIONS UNDER WHICH HYSTERECTOMY IS PERFORMED</i>	58
Other Options to Hysterectomy	58
Nerve Block	58
Medication Therapy	59

TOPIC	PAGE NO.
Myomectomy	59
Ablation	59
Balloon Therapy	59
Hysterectomy Surgical Procedures	59
<i>TABLE 24 TYPES OF HYSTERECTOMY PROCEDURES</i>	60
Radiation Therapy	60
Radiation Therapy for Endometrial Cancer	61
<i>TABLE 25 TWO TYPES OF RADIATION THERAPY TO TREAT ENDOMETRIAL CANCER</i>	61
<i>TABLE 26 RADIATION THERAPY: SIDE EFFECTS</i>	61
Risks	62
<i>TABLE 27 SIDE EFFECTS OF RADIATION</i>	62
Chemotherapy	62
Combined Radiotherapy-Chemotherapy	63
Locoregional Recurrence	63
Advanced Disease	63
Treatment of Metastatic Disease and Relapse	64
Papillary Serous Carcinoma and Clear Cell Carcinoma	64
Hormone Therapy	65
NEW THERAPEUTICS IN DEVELOPMENT	66
<i>TABLE 28 DRUGS CURRENTLY IN USE TO TREAT UTERINE CANCERS</i>	66
<i>TABLE 29 COMBINATION PRODUCTS USED FOR TREATING UTERINE CANCER</i>	68
<i>TABLE 30 DRUGS IN THE PIPELINE</i>	70
CONCLUSIONS	71
CHAPTER 7 UTERINE CANCER INCIDENCE	73
<i>TABLE 31 KEY FACTS: CANCER</i>	73
<i>TABLE 32 PREVENTION STRATEGIES</i>	75
EARLY DETECTION	75
SCREENING	75
TREATMENT	75
UTERINE CANCER GLOBAL INCIDENCE	76
<i>TABLE 33 GLOBAL INCIDENCE OF UTERINE CANCER, 2008-2018</i>	76
<i>TABLE 34 GLOBAL CORPUS UTERINE CANCER (C54) 2008 ESTIMATES: WORLD AGE-STANDARDIZED INCIDENCE RATES PER 100,000 WOMEN BY REGION</i>	77
<i>TABLE 35 UNITED KINGDOM: AGE-STANDARDIZED RATES AND NUMBER OF UTERINE CANCER DIAGNOSES PER 100,000 WOMEN, 2007 AND 2030</i>	78
NORTHERN AMERICA	79
United States	79
<i>TABLE 36 UNITED STATES: UTERINE CANCER INCIDENCE AND MORTALITY, 2011-2013</i>	79
<i>TABLE 37 KEY FINDINGS</i>	80
INCIDENCE AND MORTALITY	81
Surveillance, Epidemiology and End Results (SEER) Incidence	81
<i>TABLE 38 INCIDENCE RATES BY RACE</i>	81
U.S. Mortality	81
<i>TABLE 39 DEATH RATES BY RACE</i>	82
SURVIVAL AND STAGE	82

TOPIC	PAGE NO.
<i>TABLE 40 STAGE DISTRIBUTION AND FIVE-YEAR RELATIVE SURVIVAL OF ALL RACES BY STAGE AT DIAGNOSIS, 2003-2009 (%)</i>	82
LIFETIME RISK	83
PREVALENCE	83
INTERVENTIONS ASSOCIATED WITH DECREASED RISK	83
Oral Contraceptives	83
Physical Activity	84
Increasing Parity and Lactation	84
INTERVENTIONS ASSOCIATED WITH INCREASED RISK	84
Endogenous Estrogen	84
Exogenous Estrogen: Postmenopausal Hormone Therapy (HT)	84
Combination Estrogen-Progestin Replacement Therapy	85
Selective Estrogen Receptor Modulators (SERMs): Tamoxifen and Raloxifene	85
Obesity	86
Increasing Age	86
Genetic Predisposition	86
INTERVENTIONS OF UNPROVEN OR DISPROVEN EFFECT ON RISK	86
Weight Loss	86
Fruits, Vegetables and Vitamins	87
EUROPE	87
Trends in Postmenopausal Women	88
Trends in Premenopausal Women	89
United Kingdom	90
<i>TABLE 41 UNITED KINGDOM UTERINE CANCER INCIDENCE, NUMBER OF NEW CASES, CRUDE AND EUROPEAN AGE-STANDARDIZED (AS) INCIDENCE RATES PER 100,000 POPULATION, 2008</i>	91
<i>TABLE 42 UNITED KINGDOM: GYNECOLOGICAL CANCERS, NUMBER OF NEW CASES AND EUROPEAN AGE-STANDARDIZED (AS) INCIDENCE RATES PER 100,000 POPULATION, 2008</i>	91
INDIA	92
CHAPTER 8 GLOBAL MARKET FOR UTERINE CANCER TREATMENTS AND DIAGNOSTICS	94
CANCER: GLOBAL COSTS	94
CANCER IN THE UNITED STATES	95
<i>TABLE 43 UNITED STATES: NUMBER OF CANCER SURVIVORS, 2010 AND 2020 (NUMBER%)</i>	95
<i>TABLE 44 UNITED STATES: PROJECTED COST OF UTERINE CANCER CARE, 2010 AND 2020 (\$ MILLIONS/%)</i>	96
<i>TABLE 45 UNITED STATES: NUMBER OF UTERINE CANCER SURVIVORS, 2010 AND 2020 (NUMBER/%)</i>	97
<i>TABLE 46 UNITED STATES: NUMBER OF SURVIVORS OF GYNECOLOGICAL CANCERS BY TYPE, 2010 AND 2020 (NUMBER/%)</i>	97
CURRENT ENDOMETRIAL CANCER SCREENING AND DIAGNOSIS	98
SCREENING	98
<i>TABLE 47 CURRENT TESTS FOR UTERINE CANCER</i>	98
DIAGNOSIS	98
GLOBAL MARKET FOR UTERINE CANCER DIAGNOSTIC TESTS	99

TOPIC	PAGE NO.
<i>TABLE 48 GLOBAL UTERINE CANCER DIAGNOSTIC TESTS: MARKET AND FORECAST, THROUGH 2018 (\$ MILLIONS)</i>	99
<i>FIGURE 1 GLOBAL UTERINE CANCER DIAGNOSTIC TESTS: MARKET AND FORECAST, 2012-2018 (\$ MILLIONS)</i>	99
GLOBAL MARKET FOR ENDOMETRIAL SAMPLING	100
<i>TABLE 49 GLOBAL MARKET FOR ENDOMETRIAL BIOPSY FOR UTERINE CANCER: SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)</i>	101
<i>FIGURE 2 GLOBAL MARKET FOR ENDOMETRIAL BIOPSY FOR UTERINE CANCER: SALES AND FORECAST 2012-2018 (\$ MILLIONS)</i>	101
Dilation and Curettage	101
GLOBAL MARKET FOR HYSTEROSCOPIES	102
<i>TABLE 50 GLOBAL MARKET FOR HYSTEROSCOPIES TO TREAT UTERINE CANCER: SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)</i>	102
<i>FIGURE 3 GLOBAL MARKET FOR HYSTEROSCOPIES TO TREAT UTERINE CANCER: SALES AND FORECAST, 2012-2018 (\$ MILLIONS)</i>	102
U.S. Market for Hysteroscopies	103
<i>TABLE 51 U.S. MARKET FOR HYSTEROSCOPIES TO TREAT UTERINE CANCER: SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)</i>	103
<i>FIGURE 4 U.S. MARKET FOR HYSTEROSCOPIES TO TREAT UTERINE CANCER: SALES AND FORECAST, 2012-2018 (\$ MILLIONS)</i>	103
Testing of Endometrial Tissue	104
GLOBAL PAP SMEAR TEST MARKET	104
<i>TABLE 52 CURRENT CERVICAL CANCER SCREENING</i>	105
<i>TABLE 53 GLOBAL CANCER DIAGNOSTIC TESTS: PAP SMEAR TEST, MARKET AND FORECAST, THROUGH 2018 (\$ MILLIONS)</i>	106
<i>FIGURE 5 GLOBAL CANCER DIAGNOSTIC TESTS: PAP SMEAR TEST MARKET AND FORECAST, 2012-2018 (\$ MILLIONS)</i>	106
U.S. PAP SMEAR MARKET	106
<i>TABLE 54 NUMBER OF PAP SMEAR TESTS PERFORMED IN THE U.S. AND EUROPE, 2012 AND 2013 (\$ MILLIONS)</i>	107
<i>TABLE 55 U.S.: PERCENTAGE OF PAP SMEAR TESTS PERFORMED, 2008 AND 2010</i>	107
<i>TABLE 56 U.S.: PERCENTAGE OF WOMEN WHO RECEIVE PAP SMEAR TESTS, AGE-STRATIFIED, 2008 AND 2010</i>	108
<i>TABLE 57 PAP TESTS ORDERED OR PROVIDED IN THE U.S., 2010</i>	108
<i>TABLE 58 PAP TESTS ORDERED OR PROVIDED AT OUTPATIENT VISITS IN THE U.S., 2010</i>	109
GLOBAL COST OF PAP SMEARS	109
LATEST TECHNOLOGY	109
GLOBAL MARKET FOR TRANSVAGINAL ULTRASOUND	110
<i>TABLE 59 GLOBAL MARKET FOR TRANSVAGINAL ULTRASOUNDS: SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)</i>	112
<i>FIGURE 6 GLOBAL MARKET FOR TRANSVAGINAL ULTRASOUNDS: SALES AND FORECAST, 2012-2018 (\$ MILLIONS)</i>	112
U.S. MARKET FOR TRANSVAGINAL ULTRASOUNDS	113
<i>TABLE 60 U.S. MARKET FOR TRANSVAGINAL ULTRASOUNDS: SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)</i>	113
<i>FIGURE 7 U.S. MARKET FOR TRANSVAGINAL ULTRASOUNDS: SALES AND FORECAST, 2012-2018 (\$ MILLIONS)</i>	113
OTHER TESTS FOR ENDOMETRIAL CANCER	113
Cystoscopy and Proctoscopy	113
OTHER IMAGING TESTS	114

TOPIC	PAGE NO.
<i>TABLE 61 IMAGING TESTS</i>	114
Magnetic Resonance Imaging (MRI)	114
Positron Emission Tomography (PET)	115
Chest X-ray	115
Blood Tests	115
Complete Blood Count	115
GLOBAL MARKET FOR COMPUTED TOMOGRAPHY (CT)	115
<i>TABLE 62 GLOBAL COMPUTED TOMOGRAPHY IMAGING MARKET FOR UTERINE CANCER: SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)</i>	116
<i>FIGURE 8 GLOBAL COMPUTED TOMOGRAPHY IMAGING MARKET FOR UTERINE CANCER: SALES AND FORECAST, 2012-2018 (\$ MILLIONS)</i>	116
U.S. MARKET FOR COMPUTED TOMOGRAPHY (CT)	116
<i>TABLE 63 U.S. COMPUTED TOMOGRAPHY IMAGING MARKET FOR CANCER: SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)</i>	117
<i>FIGURE 9 U.S. COMPUTED TOMOGRAPHY IMAGING MARKET FOR CANCER: SALES AND FORECAST, 2012-2018 (\$ MILLIONS)</i>	117
GLOBAL CA-125 TEST MARKET	117
<i>TABLE 64 ELEVATED CA-125 LEVEL</i>	118
<i>TABLE 65 GLOBAL DIAGNOSTIC MARKET FOR CA-125 TESTS: SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)</i>	119
<i>FIGURE 10 GLOBAL DIAGNOSTIC MARKET FOR CA-125 TESTS: SALES AND FORECAST, 2012-2018 (\$ MILLIONS)</i>	119
U.S. CA-125 TEST MARKET	119
<i>TABLE 66 U.S. DIAGNOSTIC MARKET FOR CA-125 TESTS: SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)</i>	120
<i>FIGURE 11 U.S. DIAGNOSTIC MARKET FOR CA-125 TESTS: SALES AND FORECAST, 2012-2018 (\$ MILLIONS)</i>	120
GENETIC TESTING	120
<i>TABLE 67 GENETIC COUNSELING MAY BE RECOMMENDED</i>	121
MOLECULAR DIAGNOSTICS	121
PAPGENE TEST	121
CONCLUSIONS	122
CHAPTER 9 TREATMENT MARKET	125
ENDOMETRIAL CANCER: CURRENT PRACTICES	125
<i>TABLE 68 SEVERAL RECOGNIZED PATHOLOGIC AND CLINICAL FACTORS FOR RISK OF RELAPSE AFTER SURGERY</i>	125
GLOBAL MARKET FOR ENDOMETRIAL CANCER TREATMENTS	126
<i>TABLE 69 GLOBAL ENDOMETRIAL CANCER MARKET: SALES AND FORECAST BY APPLICATION TYPE, THROUGH 2018 (\$ MILLIONS)</i>	126
<i>FIGURE 12 GLOBAL ENDOMETRIAL CANCER MARKET: SALES AND FORECAST BY APPLICATION TYPE, 2012-2018 (\$ MILLIONS)</i>	126
GLOBAL MARKET FOR RADIATION THERAPY TO TREAT UTERINE CANCER	127
Vaginal Brachytherapy	127
<i>TABLE 70 TYPES OF VAGINAL BRACHYTHERAPY</i>	127
External Beam Radiation Therapy	128
<i>TABLE 71 SIDE EFFECTS OF RADIATION THERAPY</i>	128
<i>TABLE 72 GLOBAL MARKET FOR RADIATION USED TO TREAT UTERINE CANCER: SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)</i>	129

TOPIC	PAGE NO.
<i>FIGURE 13 GLOBAL MARKET FOR RADIATION USED TO TREAT UTERINE CANCER: SALES AND FORECAST, 2012-2018 (\$ MILLIONS)</i>	129
U.S. Market for Radiation Therapy to Treat Uterine Cancer	130
<i>TABLE 73 U.S. MARKET FOR RADIATION USED TO TREAT UTERINE CANCER: SALES AND FORECAST, THROUGH 2018c (\$ MILLIONS)</i>	131
<i>FIGURE 14 U.S. MARKET FOR RADIATION USED TO TREAT UTERINE CANCER MARKET: SALES AND FORECAST, 2012-2018 (\$ MILLIONS)</i>	131
CHEMOTHERAPY	132
<i>TABLE 74 COMMON SIDE EFFECTS OF CHEMOTHERAPY</i>	132
GLOBAL UTERINE DRUG TREATMENT MARKET	132
<i>TABLE 75 GLOBAL MARKET FOR DRUGS TO TREAT UTERINE CANCER, THROUGH 2018 (\$ MILLIONS)</i>	133
GLOBAL MARKET FOR CYTOTOXIC THERAPIES	133
<i>TABLE 76 CYTOTOXIC THERAPIES: INDICATIONS</i>	134
<i>TABLE 77 GLOBAL CYTOTOXIC MARKET, 2010 AND 2017 (\$ MILLIONS)</i>	134
<i>FIGURE 15 GLOBAL CYTOTOXIC THERAPY MARKET, 2010 AND 2017 (\$ MILLIONS)</i>	134
U.S. Market for Cytotoxic Therapies	135
<i>TABLE 78 U.S. CYTOTOXIC THERAPY MARKET, THROUGH 2018 (\$ MILLIONS)</i>	135
<i>FIGURE 16 U.S. CYTOTOXIC THERAPY MARKET, 2012-2018 (\$ MILLIONS)</i>	135
European Market for Cytotoxic Therapies	135
<i>TABLE 79 EUROPEAN CYTOTOXIC THERAPY MARKET, THROUGH 2018 (\$ MILLIONS)</i>	136
<i>FIGURE 17 EUROPEAN CYTOTOXIC THERAPY MARKET, 2012-2018 (\$ MILLIONS)</i>	136
Japanese Market for Cytotoxic Therapies	136
<i>TABLE 80 JAPANESE CYTOTOXIC THERAPY MARKET, THROUGH 2018 (\$ MILLIONS)</i>	137
<i>FIGURE 18 JAPANESE CYTOTOXIC THERAPY MARKET, 2012-2018 (\$ MILLIONS)</i>	137
Drawbacks of Chemotherapy	137
Drugs Used in Chemotherapy	138
<i>TABLE 81 DRUGS USED TO TREAT UTERINE CANCER</i>	138
Paclitaxel	138
<i>TABLE 82 UTERINE CANCER: CISPLATIN SALES, 2010 (\$ MILLIONS)</i>	139
Carboplatin	139
<i>TABLE 83 UTERINE CANCER: CARBOPLATIN SALES, 2010-2012 (\$ MILLIONS)</i>	139
Cisplatin	139
Hycamtin	140
<i>TABLE 84 UTERINE CANCER: HYCAMTIN SALES, 2010-2012 (\$ MILLIONS)</i>	140
Avastin	140
<i>TABLE 85 UTERINE CANCER: AVASTIN SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)</i>	141
Cisplatin + Paclitaxel	141
Depo-Provera	141
Megestrol + Tamoxifen	142
AEZS-108	142
Ixabepilone	142
Ridaforolimus (Deforolimus, AP23573)	143
SAR245408 (XL147)	145
HORMONE THERAPY FOR ENDOMETRIAL CANCER	145
Progestins	145
Tamoxifen	145

TOPIC	PAGE NO.
Gonadotropin-releasing Hormone Agonists	145
Aromatase Inhibitors	146
UTERINE CANCER MARKET AND CHINA	146
UTERINE CANCER MARKET AND INDIA	146
Hysterectomies in India	146
<i>TABLE 86 COSTS OF A HYSTERECTOMY IN INDIA COMPARED WITH THE COSTS IN THE U.S., 2012 (\$)</i>	147
ENDOMETRIAL CANCER IN YOUNG WOMEN	147
CANCER IN THE OBESE PATIENT OR MEDICALLY INOPERABLE WOMAN	147
INCOMPLETELY STAGED PATIENTS	147
TREATING MENOPAUSAL SYMPTOMS	148
SURGICAL TREATMENTS OF ENDOMETRIAL CANCER	148
Incidence of Hysterectomy	148
<i>TABLE 87 ESTIMATED NUMBER OF HYSTERECTOMIES PERFORMED ANNUALLY WORLDWIDE</i>	148
<i>TABLE 88 ESTIMATED NUMBER OF HYSTERECTOMIES PERFORMED ANNUALLY IN NORTH AMERICA</i>	149
<i>TABLE 89 ESTIMATED NUMBER OF HYSTERECTOMIES PERFORMED ANNUALLY IN CENTRAL AMERICA</i>	149
<i>TABLE 90 ESTIMATED NUMBER OF HYSTERECTOMIES PERFORMED ANNUALLY IN SOUTH AMERICA,</i>	150
<i>TABLE 91 ESTIMATED NUMBER OF HYSTERECTOMIES PERFORMED ANNUALLY IN EUROPE</i>	150
<i>TABLE 92 ESTIMATED NUMBER OF HYSTERECTOMIES PERFORMED ANNUALLY IN ASIA</i>	151
<i>TABLE 93 ESTIMATED NUMBER OF HYSTERECTOMIES PERFORMED ANNUALLY IN THE MIDDLE EAST</i>	152
<i>TABLE 94 ESTIMATED NUMBER OF HYSTERECTOMIES PERFORMED ANNUALLY IN NORTHERN AFRICA</i>	152
<i>TABLE 95 ESTIMATED NUMBER OF HYSTERECTOMIES PERFORMED ANNUALLY IN THE OCEANIA REGION</i>	153
Robotic Surgery	154
<i>TABLE 96 HYSTERECTOMY FACTS</i>	155
da Vinci System	155
Incidence of Hysterectomy in the United Kingdom	156
Global Incidence of Hysterectomy	156
<i>TABLE 97 GLOBAL ESTIMATES OF THE NUMBER OF HYSTERECTOMIES PERFORMED ANNUALLY BY TYPE</i>	156
UTERINE CANCER SURGERY MARKET	157
Revenues from Hysterectomies	157
<i>TABLE 98 ESTIMATED GLOBAL REVENUES FROM HYSTERECTOMY PROCEDURES BY TYPE, 2013 (\$ MILLIONS)</i>	157
<i>TABLE 99 UNITED STATES AND CANADA: NUMBER OF HYSTERECTOMY PROCEDURES PERFORMED ANNUALLY BY TYPE, 2013 ESTIMATES</i>	157
<i>TABLE 100 UNITED STATES AND CANADA: HYSTERECTOMY PROCEDURES: SALES AND FORECAST, 2013 (\$ MILLIONS)</i>	158
<i>TABLE 101 KEY EUROPEAN COUNTRIES: HYSTERECTOMY PROCEDURES: SALES AND FORECAST, 2013 (\$ MILLIONS)</i>	158
<i>TABLE 102 KEY ASIAN COUNTRIES: HYSTERECTOMY PROCEDURES: SALES AND FORECAST 2013 (\$ MILLIONS)</i>	159

TOPIC	PAGE NO.
Revenues from Hysterectomies by Type	159
<i>TABLE 103 GLOBAL MARKET FOR HYSTERECTOMIES TO TREAT UTERINE CANCER: SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)</i>	159
<i>FIGURE 19 GLOBAL MARKET FOR HYSTERECTOMIES TO TREAT UTERINE CANCER: SALES AND FORECAST, 2012-2018 (\$ MILLIONS)</i>	159
U.S. Revenues from Hysterectomies by Type	160
<i>TABLE 104 U.S. MARKET FOR HYSTERECTOMIES TO TREAT UTERINE CANCER: SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)</i>	160
<i>FIGURE 20 U.S. MARKET FOR HYSTERECTOMIES TO TREAT UTERINE CANCER: SALES AND FORECAST, 2011-2018</i>	160
Hysterectomies in India	161
ALTERNATE THERAPIES	161
Uterine Balloon Therapy	161
Myomectomy	161
Transcervical Resection of Endometrium (TCRE)	162
Hysteroscopic Polypectomy	162
Mirena (Hormone Loaded Intrauterine Device)	162
Agonadotropin-Releasing Hormone Agonist (GnRH Agonist)	162
Uterine Artery Embolization (UAE)	163
MRI Guided Focused Ultrasound	163
CT Scan	163
CONCLUSION	163
CHAPTER 10 PATENT LANDSCAPE	166
GLOBAL IMPACT OF PATENT EXPIRIES	166
PATENT LANDSCAPE	166
HYCAMTIN (TOPOTECAN HYDROCHLORIDE)	167
<i>TABLE 105 PATENT EXPIRIES ON CANCER CHEMOTHERAPY DRUGS</i>	167
CISPLATIN	168
AVASTIN	168
CHAPTER 11 SELECTED COMPANY PROFILES	170
ABBOTT LABORATORIES	170
AETERNA ZENTARIS INC.	170
ASTRAZENECA	170
BECTON, DICKINSON AND CO.	171
BRISTOL-MYERS SQUIBB	171
EXELIXIS	171
FEMASYS	172
GLAXOSMITHKLINE	172
INTUITIVE SURGICAL	172
JOHNSON & JOHNSON	172
MERCK	173
ORYZON GENOMICS	173
PFIZER	174
QIAGEN	174
QUEST DIAGNOSTICS	175
RJ MADRID	175

TOPIC	PAGE NO.
ROCHE DIAGNOSTICS	176
SANOFI	176
SIEMENS AG	176
TAJ PHARMACEUTICALS	176
TEVA PHARMACEUTICAL INDUSTRIES	177
VARIAN MEDICAL SYSTEMS	177
CHAPTER 12 BIBLIOGRAPHY	179

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE UTERINE/ENDOMETRIAL CANCER: TREATMENT AND DIAGNOSTICS, GLOBAL MARKET AND FORECAST, THROUGH 2018 (\$ MILLIONS)	8
TABLE 1 LIFESTYLE CHANGES THAT HELP REDUCE THE PREVALENCE OF CANCER	12
TABLE 2 KEY CLINICAL FEATURES OF UTERINE CANCER	13
TABLE 3 HISTOLOGY OF ADENOCARCINOMA	15
TABLE 4 RISK FACTORS	16
TABLE 5 GENES: CAUSE OF HEREDITARY NONPOLYPOSIS COLON CANCER (HNPCC)	20
TABLE 6 ENDOMETRIAL CARCINOMAS CLASSIFIED INTO TWO PATHOGENETIC GROUPS	21
TABLE 7 CARCINOMA OF THE ENDOMETRIUM	22
TABLE 8 SIGNS AND SYMPTOMS	23
TABLE 9 UTERINE CANCER: DIAGNOSIS	24
TABLE 10 DIAGNOSTIC TESTS	24
TABLE 11 STAGES OF ENDOMETRIAL CANCER	25
TABLE 12 TREATMENT DEPENDS UPON THE STAGE	26
TABLE 13 FIVE-YEAR SURVIVAL RATES (%)	29
TABLE 14 UTERINE CARCINOSARCOMA: FIVE-YEAR SURVIVAL RATES BY STAGE (%)	29
TABLE 15 TYPES OF UTERINE CANCERS	33
TABLE 16 GRADING	35
TABLE 17 IMPORTANT GYNECOLOGIC TUMOR MARKERS	37
TABLE 18 POTENTIAL GYNECOLOGIC TUMOR MARKERS	37
TABLE 19 UTERINE CANCER GENOMIC SUBTYPES: KEY CHARACTERISTICS	42
TABLE 20 STAGING OF UTERINE CANCER	46
TABLE 21 UTERINE CANCER SCREENING TESTS OR PROCEDURES	48
TABLE 22 GYNECDX KEY FEATURES	52
TABLE 23 CONDITIONS UNDER WHICH HYSTERECTOMY IS PERFORMED	58
TABLE 24 TYPES OF HYSTERECTOMY PROCEDURES	60
TABLE 25 TWO TYPES OF RADIATION THERAPY TO TREAT ENDOMETRIAL CANCER	61
TABLE 26 RADIATION THERAPY: SIDE EFFECTS	61
TABLE 27 SIDE EFFECTS OF RADIATION	62
TABLE 28 DRUGS CURRENTLY IN USE TO TREAT UTERINE CANCERS	66
TABLE 29 COMBINATION PRODUCTS USED FOR TREATING UTERINE CANCER	68
TABLE 30 DRUGS IN THE PIPELINE	70
TABLE 31 KEY FACTS: CANCER	73
TABLE 32 PREVENTION STRATEGIES	75
TABLE 33 GLOBAL INCIDENCE OF UTERINE CANCER, 2008-2018	76
TABLE 34 GLOBAL CORPUS UTERINE CANCER (C54) 2008 ESTIMATES: WORLD AGE-STANDARDIZED INCIDENCE RATES PER 100,000 WOMEN BY REGION	77
TABLE 35 UNITED KINGDOM: AGE-STANDARDIZED RATES AND NUMBER OF UTERINE CANCER DIAGNOSES PER 100,000 WOMEN, 2007 AND 2030	78
TABLE 36 UNITED STATES: UTERINE CANCER INCIDENCE AND MORTALITY, 2011-2013	79
TABLE 37 KEY FINDINGS	80
TABLE 38 INCIDENCE RATES BY RACE	81
TABLE 39 DEATH RATES BY RACE	82
TABLE 40 STAGE DISTRIBUTION AND FIVE-YEAR RELATIVE SURVIVAL OF ALL RACES BY STAGE AT DIAGNOSIS, 2003-2009 (%)	82

TABLE HEADING	PAGE NO.
TABLE 41 UNITED KINGDOM UTERINE CANCER INCIDENCE, NUMBER OF NEW CASES, CRUDE AND EUROPEAN AGE-STANDARDIZED (AS) INCIDENCE RATES PER 100,000 POPULATION, 2008	91
TABLE 42 UNITED KINGDOM: GYNECOLOGICAL CANCERS, NUMBER OF NEW CASES AND EUROPEAN AGE-STANDARDIZED (AS) INCIDENCE RATES PER 100,000 POPULATION, 2008	91
TABLE 43 UNITED STATES: NUMBER OF CANCER SURVIVORS, 2010 AND 2020 (NUMBER%)	95
TABLE 44 UNITED STATES: PROJECTED COST OF UTERINE CANCER CARE, 2010 AND 2020 (\$ MILLIONS/%)	96
TABLE 45 UNITED STATES: NUMBER OF UTERINE CANCER SURVIVORS, 2010 AND 2020 (NUMBER/%)	97
TABLE 46 UNITED STATES: NUMBER OF SURVIVORS OF GYNECOLOGICAL CANCERS BY TYPE, 2010 AND 2020 (NUMBER/%)	97
TABLE 47 CURRENT TESTS FOR UTERINE CANCER	98
TABLE 48 GLOBAL UTERINE CANCER DIAGNOSTIC TESTS: MARKET AND FORECAST, THROUGH 2018 (\$ MILLIONS)	99
TABLE 49 GLOBAL MARKET FOR ENDOMETRIAL BIOPSY FOR UTERINE CANCER: SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)	101
TABLE 50 GLOBAL MARKET FOR HYSTEROSCOPIES TO TREAT UTERINE CANCER: SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)	102
TABLE 51 U.S. MARKET FOR HYSTEROSCOPIES TO TREAT UTERINE CANCER: SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)	103
TABLE 52 CURRENT CERVICAL CANCER SCREENING	105
TABLE 53 GLOBAL CANCER DIAGNOSTIC TESTS: PAP SMEAR TEST, MARKET AND FORECAST, THROUGH 2018 (\$ MILLIONS)	106
TABLE 54 NUMBER OF PAP SMEAR TESTS PERFORMED IN THE U.S. AND EUROPE, 2012 AND 2013 (\$ MILLIONS)	107
TABLE 55 U.S.: PERCENTAGE OF PAP SMEAR TESTS PERFORMED, 2008 AND 2010	107
TABLE 56 U.S.: PERCENTAGE OF WOMEN WHO RECEIVE PAP SMEAR TESTS, AGE-STRATIFIED, 2008 AND 2010	108
TABLE 57 PAP TESTS ORDERED OR PROVIDED IN THE U.S., 2010	108
TABLE 58 PAP TESTS ORDERED OR PROVIDED AT OUTPATIENT VISITS IN THE U.S., 2010	109
TABLE 59 GLOBAL MARKET FOR TRANSVAGINAL ULTRASOUNDS: SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)	112
TABLE 60 U.S. MARKET FOR TRANSVAGINAL ULTRASOUNDS: SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)	113
TABLE 61 IMAGING TESTS	114
TABLE 62 GLOBAL COMPUTED TOMOGRAPHY IMAGING MARKET FOR UTERINE CANCER: SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)	116
TABLE 63 U.S. COMPUTED TOMOGRAPHY IMAGING MARKET FOR CANCER: SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)	117
TABLE 64 ELEVATED CA-125 LEVEL	118
TABLE 65 GLOBAL DIAGNOSTIC MARKET FOR CA-125 TESTS: SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)	119
TABLE 66 U.S. DIAGNOSTIC MARKET FOR CA-125 TESTS: SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)	120
TABLE 67 GENETIC COUNSELING MAY BE RECOMMENDED	121
TABLE 68 SEVERAL RECOGNIZED PATHOLOGIC AND CLINICAL FACTORS FOR RISK OF RELAPSE AFTER SURGERY	125

TABLE HEADING	PAGE NO.
TABLE 69 GLOBAL ENDOMETRIAL CANCER MARKET: SALES AND FORECAST BY APPLICATION TYPE, THROUGH 2018 (\$ MILLIONS)	126
TABLE 70 TYPES OF VAGINAL BRACHYTHERAPY	127
TABLE 71 SIDE EFFECTS OF RADIATION THERAPY	128
TABLE 72 GLOBAL MARKET FOR RADIATION USED TO TREAT UTERINE CANCER: SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)	129
TABLE 73 U.S. MARKET FOR RADIATION USED TO TREAT UTERINE CANCER: SALES AND FORECAST, THROUGH 2018C (\$ MILLIONS)	131
TABLE 74 COMMON SIDE EFFECTS OF CHEMOTHERAPY	132
TABLE 75 GLOBAL MARKET FOR DRUGS TO TREAT UTERINE CANCER, THROUGH 2018 (\$ MILLIONS)	133
TABLE 76 CYTOTOXIC THERAPIES: INDICATIONS	134
TABLE 77 GLOBAL CYTOTOXIC MARKET, 2010 AND 2017 (\$ MILLIONS)	134
TABLE 78 U.S. CYTOTOXIC THERAPY MARKET, THROUGH 2018 (\$ MILLIONS)	135
TABLE 79 EUROPEAN CYTOTOXIC THERAPY MARKET, THROUGH 2018 (\$ MILLIONS)	136
TABLE 80 JAPANESE CYTOTOXIC THERAPY MARKET, THROUGH 2018 (\$ MILLIONS)	137
TABLE 81 DRUGS USED TO TREAT UTERINE CANCER	138
TABLE 82 UTERINE CANCER: CISPLATIN SALES, 2010 (\$ MILLIONS)	139
TABLE 83 UTERINE CANCER: CARBOPLATIN SALES, 2010-2012 (\$ MILLIONS)	139
TABLE 84 UTERINE CANCER: HYCAMTIN SALES, 2010-2012 (\$ MILLIONS)	140
TABLE 85 UTERINE CANCER: AVASTIN SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)	141
TABLE 86 COSTS OF A HYSTERECTOMY IN INDIA COMPARED WITH THE COSTS IN THE U.S., 2012 (\$)	147
TABLE 87 ESTIMATED NUMBER OF HYSTERECTOMIES PERFORMED ANNUALLY WORLDWIDE	148
TABLE 88 ESTIMATED NUMBER OF HYSTERECTOMIES PERFORMED ANNUALLY IN NORTH AMERICA	149
TABLE 89 ESTIMATED NUMBER OF HYSTERECTOMIES PERFORMED ANNUALLY IN CENTRAL AMERICA	149
TABLE 90 ESTIMATED NUMBER OF HYSTERECTOMIES PERFORMED ANNUALLY IN SOUTH AMERICA,	150
TABLE 91 ESTIMATED NUMBER OF HYSTERECTOMIES PERFORMED ANNUALLY IN EUROPE	150
TABLE 92 ESTIMATED NUMBER OF HYSTERECTOMIES PERFORMED ANNUALLY IN ASIA	151
TABLE 93 ESTIMATED NUMBER OF HYSTERECTOMIES PERFORMED ANNUALLY IN THE MIDDLE EAST	152
TABLE 94 ESTIMATED NUMBER OF HYSTERECTOMIES PERFORMED ANNUALLY IN NORTHERN AFRICA	152
TABLE 95 ESTIMATED NUMBER OF HYSTERECTOMIES PERFORMED ANNUALLY IN THE OCEANIA REGION	153
TABLE 96 HYSTERECTOMY FACTS	155
TABLE 97 GLOBAL ESTIMATES OF THE NUMBER OF HYSTERECTOMIES PERFORMED ANNUALLY BY TYPE	156
TABLE 98 ESTIMATED GLOBAL REVENUES FROM HYSTERECTOMY PROCEDURES BY TYPE, 2013 (\$ MILLIONS)	157
TABLE 99 UNITED STATES AND CANADA: NUMBER OF HYSTERECTOMY PROCEDURES PERFORMED ANNUALLY BY TYPE, 2013 ESTIMATES	157
TABLE 100 UNITED STATES AND CANADA: HYSTERECTOMY PROCEDURES: SALES AND FORECAST, 2013 (\$ MILLIONS)	158

TABLE HEADING	PAGE NO.
TABLE 101 KEY EUROPEAN COUNTRIES: HYSTERECTOMY PROCEDURES: SALES AND FORECAST, 2013 (\$ MILLIONS)	158
TABLE 102 KEY ASIAN COUNTRIES: HYSTERECTOMY PROCEDURES: SALES AND FORECAST 2013 (\$ MILLIONS)	159
TABLE 103 GLOBAL MARKET FOR HYSTERECTOMIES TO TREAT UTERINE CANCER: SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)	159
TABLE 104 U.S. MARKET FOR HYSTERECTOMIES TO TREAT UTERINE CANCER: SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)	160
TABLE 105 PATENT EXPIRIES ON CANCER CHEMOTHERAPY DRUGS	167

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE UTERINE/ENDOMETRIAL CANCER: TREATMENT AND DIAGNOSTICS, GLOBAL MARKET AND FORECAST, 2012-2018 (\$ MILLIONS)	9
FIGURE 1 GLOBAL UTERINE CANCER DIAGNOSTIC TESTS: MARKET AND FORECAST, 2012-2018 (\$ MILLIONS)	99
FIGURE 2 GLOBAL MARKET FOR ENDOMETRIAL BIOPSY FOR UTERINE CANCER: SALES AND FORECAST 2012-2018 (\$ MILLIONS)	101
FIGURE 3 GLOBAL MARKET FOR HYSTEROSCOPIES TO TREAT UTERINE CANCER: SALES AND FORECAST, 2012-2018 (\$ MILLIONS)	102
FIGURE 4 U.S. MARKET FOR HYSTEROSCOPIES TO TREAT UTERINE CANCER: SALES AND FORECAST, 2012-2018 (\$ MILLIONS)	103
FIGURE 5 GLOBAL CANCER DIAGNOSTIC TESTS: PAP SMEAR TEST MARKET AND FORECAST, 2012-2018 (\$ MILLIONS)	106
FIGURE 6 GLOBAL MARKET FOR TRANSVAGINAL ULTRASOUNDS: SALES AND FORECAST, 2012-2018 (\$ MILLIONS)	112
FIGURE 7 U.S. MARKET FOR TRANSVAGINAL ULTRASOUNDS: SALES AND FORECAST, 2012-2018 (\$ MILLIONS)	113
FIGURE 8 GLOBAL COMPUTED TOMOGRAPHY IMAGING MARKET FOR UTERINE CANCER: SALES AND FORECAST, 2012-2018 (\$ MILLIONS)	116
FIGURE 9 U.S. COMPUTED TOMOGRAPHY IMAGING MARKET FOR CANCER: SALES AND FORECAST, 2012-2018 (\$ MILLIONS)	117
FIGURE 10 GLOBAL DIAGNOSTIC MARKET FOR CA-125 TESTS: SALES AND FORECAST, 2012-2018 (\$ MILLIONS)	119
FIGURE 11 U.S. DIAGNOSTIC MARKET FOR CA-125 TESTS: SALES AND FORECAST, 2012-2018 (\$ MILLIONS)	120
FIGURE 12 GLOBAL ENDOMETRIAL CANCER MARKET: SALES AND FORECAST BY APPLICATION TYPE, 2012-2018 (\$ MILLIONS)	126
FIGURE 13 GLOBAL MARKET FOR RADIATION USED TO TREAT UTERINE CANCER: SALES AND FORECAST, 2012-2018 (\$ MILLIONS)	129
FIGURE 14 U.S. MARKET FOR RADIATION USED TO TREAT UTERINE CANCER MARKET: SALES AND FORECAST, 2012-2018 (\$ MILLIONS)	131
FIGURE 15 GLOBAL CYTOTOXIC THERAPY MARKET, 2010 AND 2017 (\$ MILLIONS)	134
FIGURE 16 U.S. CYTOTOXIC THERAPY MARKET, 2012-2018 (\$ MILLIONS)	135
FIGURE 17 EUROPEAN CYTOTOXIC THERAPY MARKET, 2012-2018 (\$ MILLIONS)	136
FIGURE 18 JAPANESE CYTOTOXIC THERAPY MARKET, 2012-2018 (\$ MILLIONS)	137
FIGURE 19 GLOBAL MARKET FOR HYSTERECTOMIES TO TREAT UTERINE CANCER: SALES AND FORECAST, 2012-2018 (\$ MILLIONS)	159
FIGURE 20 U.S. MARKET FOR HYSTERECTOMIES TO TREAT UTERINE CANCER: SALES AND FORECAST, 2011-2018	160